{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:11:09Z","timestamp":1783923069294,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32270966"],"award-info":[{"award-number":["32270966"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370403"],"award-info":[{"award-number":["82370403"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303370"],"award-info":[{"award-number":["82303370"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403385"],"award-info":[{"award-number":["82403385"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2024SF-YBXM-057"],"award-info":[{"award-number":["2024SF-YBXM-057"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017550","name":"Shaanxi Science and Technology Association","doi-asserted-by":"publisher","award":["20240320"],"award-info":[{"award-number":["20240320"]}],"id":[{"id":"10.13039\/501100017550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bcp.2026.118101","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T13:51:12Z","timestamp":1779630672000},"page":"118101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Endothelial RNA polymerase I, which is regulated by SPEN, is a target for improving anti-PD-1 immunotherapy of cancer"],"prefix":"10.1016","volume":"251","author":[{"given":"Danni","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayulin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianchun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118101_b0005","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bcp.2026.118101_b0010","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1172\/JCI96582","article-title":"Increased vessel perfusion predicts the efficacy of immune checkpoint blockade","volume":"128","author":"Zheng","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2026.118101_b0015","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118101_b0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2026.118101_b0025","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.118101_b0030","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41568-024-00736-0","article-title":"Targeting the tumour vasculature: from vessel destruction to promotion","volume":"24","author":"Guelfi","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2026.118101_b0035","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-physiol-020518-114700","article-title":"Normalizing function of tumor vessels: progress, opportunities, and challenges","volume":"81","author":"Martin","year":"2019","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.bcp.2026.118101_b0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41577-025-01211-z","article-title":"Linking tumour angiogenesis and tumour immunity","volume":"26","author":"Kabir","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2026.118101_b0045","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118101_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117574","article-title":"Tumor vasculature-mediated formation of tertiary lymphoid structures: unraveling spatiotemporal coupling to optimize vasculo-immunotherapy","volume":"244","author":"Lei","year":"2026","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118101_b0055","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nri.2017.145","article-title":"Improving immune-vascular crosstalk for cancer immunotherapy","volume":"18","author":"Huang","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2026.118101_b0060","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aak9670","article-title":"Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade","volume":"9","author":"Schmittnaegel","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2026.118101_b0065","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.7150\/thno.112023","article-title":"Targeting endothelial MYC using siRNA or miR-218 nanoparticles sensitizes chemo- and immuno-therapies by recapitulating the Notch activation-induced tumor vessel normalization","volume":"15","author":"Yan","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2026.118101_b0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adn0904","article-title":"Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies","volume":"16","author":"Lu","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2026.118101_b0075","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118101_b0080","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1311","article-title":"Single-cell transcriptomics reveals antigen-presenting capacity and therapeutic resistance potential of immunomodulatory endothelial cells in colorectal cancer","volume":"12","author":"Wen","year":"2024","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.bcp.2026.118101_b0085","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ccell.2025.10.008","article-title":"Remodeling of T and endothelial cells during total neoadjuvant therapy in rectal cancer","volume":"43","author":"Gao","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2026.118101_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1551322","article-title":"IFN-\u03b3-mediated suppression of ANGPT2-Tie2 in endothelial cells facilitates tumor vascular normalization during immunotherapy","volume":"16","author":"Cai","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118101_b0095","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211039899","article-title":"Immune checkpoint inhibitors in ovarian cancer: where do we stand?","volume":"13","author":"Leary","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.bcp.2026.118101_b0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.49040","article-title":"Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: a randomized clinical trial","volume":"5","author":"Mettu","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.bcp.2026.118101_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100559","article-title":"MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF(wt) metastatic colorectal cancer","volume":"7","author":"Tabernero","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.bcp.2026.118101_b0110","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41556-025-01823-6","article-title":"Escape from X inactivation is directly modulated by Xist noncoding RNA","volume":"28","author":"Hauth","year":"2026","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118101_b0115","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1038\/s41467-021-27294-5","article-title":"SPEN is required for Xist upregulation during initiation of X chromosome inactivation","volume":"12","author":"Robert-Finestra","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118101_b0120","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41586-020-1974-9","article-title":"SPEN integrates transcriptional and epigenetic control of X-inactivation","volume":"578","author":"Dossin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118101_b0125","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature14443","article-title":"The Xist lncRNA interacts directly with SHARP to silence transcription through HDAC3","volume":"521","author":"McHugh","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118101_b0130","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1073\/pnas.0610520104","article-title":"Msx2-interacting nuclear target protein (Mint) deficiency reveals negative regulation of early thymocyte differentiation by Notch\/RBP-J signaling","volume":"104","author":"Tsuji","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118101_b0135","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1074-7613(03)00029-3","article-title":"Regulation of marginal zone B cell development by MINT, a suppressor of Notch\/RBP-J signaling pathway","volume":"18","author":"Kuroda","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2026.118101_b0140","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159860","article-title":"Repression of rRNA gene transcription by endothelial SPEN deficiency normalizes tumor vasculature via nucleolar stress","volume":"133","author":"Yang","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2026.118101_b0145","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ccell.2023.04.011","article-title":"Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2026.118101_b0150","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13073-023-01164-9","article-title":"Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing","volume":"15","author":"Hu","year":"2023","journal-title":"Genome Med."},{"key":"10.1016\/j.bcp.2026.118101_b0155","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41577-025-01187-w","article-title":"Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy","volume":"25","author":"Lanitis","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2026.118101_b0160","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/0008-5472.CAN-10-1728","article-title":"Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth","volume":"71","author":"Drygin","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118101_b0165","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.2147\/OTT.S104513","article-title":"CX-5461 induces autophagy and inhibits tumor growth via mammalian target of rapamycin-related signaling pathways in osteosarcoma","volume":"9","author":"Li","year":"2016","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.bcp.2026.118101_b0170","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-18-1455","article-title":"First-in-human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: results of a phase I dose-escalation study","volume":"9","author":"Khot","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118101_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2026.117828","article-title":"RNA polymerase I inhibitor CX-5461 suppresses cervical cancer cell growth by inducing DNA damage and mitotic catastrophe and enhances cisplatin sensitivity","volume":"248","author":"Liu","year":"2026","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118101_b0180","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature22311","article-title":"Tumour ischaemia by interferon-\u03b3 resembles physiological blood vessel regression","volume":"545","author":"Kammertoens","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118101_b0185","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.immuni.2017.04.015","article-title":"CD4(+) T cell activation and vascular normalization: two sides of the same coin?","volume":"46","author":"De Palma","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2026.118101_b0190","doi-asserted-by":"crossref","first-page":"9945","DOI":"10.1074\/jbc.M010303200","article-title":"Signal transduction by the chemokine receptor CXCR3: activation of Ras\/ERK, Src, and phosphatidylinositol 3-kinase\/Akt controls cell migration and proliferation in human vascular pericytes","volume":"276","author":"Bonacchi","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118101_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100856","article-title":"A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer","volume":"35","author":"Chung","year":"2023","journal-title":"Neoplasia"},{"key":"10.1016\/j.bcp.2026.118101_b0200","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1038\/s41467-022-31199-2","article-title":"Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies","volume":"13","author":"Hilton","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118101_b0205","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1186\/s12967-025-06473-8","article-title":"The G-quadruplex ligand CX-5461: an innovative candidate for disease treatment","volume":"23","author":"Li","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2026.118101_b0210","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1161\/ATVBAHA.116.308401","article-title":"Therapeutic targeting of RNA polymerase I with the small-molecule CX-5461 for prevention of arterial injury-induced neointimal hyperplasia","volume":"37","author":"Ye","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bcp.2026.118101_b0215","article-title":"RNA polymerase I inhibitor CX-5461 suppresses cervical cancer cell growth by inducing DNA damage and mitotic catastrophe and enhances cisplatin sensitivity","author":"Liu","year":"2026","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118101_b0220","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jconrel.2022.03.004","article-title":"DMPC\/Chol liposomal copper CX5461 is therapeutically superior to a DSPC\/Chol formulation","volume":"345","author":"Leung","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2026.118101_b0225","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1158\/0008-5472.CAN-12-1187","article-title":"PD-1 blockade enhances T-cell migration to tumors by elevating IFN-\u03b3 inducible chemokines","volume":"72","author":"Peng","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118101_b0230","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118101_b0235","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s43018-025-00986-3","article-title":"The tumor microenvironment's role in the response to immune checkpoint blockade","volume":"6","author":"Aliazis","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.bcp.2026.118101_b0240","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41571-025-01035-9","article-title":"The next generation of immunotherapies for lung cancers","volume":"22","author":"Zhao","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118101_b0245","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","article-title":"Vascular normalization as an emerging strategy to enhance cancer immunotherapy","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118101_b0250","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","article-title":"Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials","volume":"21","author":"Kuo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118101_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108968","article-title":"Normalization of tumor vasculature: a potential strategy to increase the efficiency of immune checkpoint blockades in cancers","volume":"110","author":"Shi","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2026.118101_b0260","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrc.2017.104","article-title":"Ribosome biogenesis in cancer: new players and therapeutic avenues","volume":"18","author":"Pelletier","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2026.118101_b0265","doi-asserted-by":"crossref","DOI":"10.3390\/cells8010055","article-title":"The ribosome biogenesis-cancer connection","volume":"8","author":"Penzo","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2026.118101_b0270","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1073\/pnas.81.15.4917","article-title":"Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts","volume":"81","author":"Collins","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226004363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226004363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:35:12Z","timestamp":1783920912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226004363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":54,"alternative-id":["S0006295226004363"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118101","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endothelial RNA polymerase I, which is regulated by SPEN, is a target for improving anti-PD-1 immunotherapy of cancer","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118101"}}